A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue

Simply Wall St.03-17

Teva Pharmaceutical Industries (TEVA) is back in focus after investors reacted to progress on its shift from a traditional generics business toward higher margin branded medicines, anchored by Austedo...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620414131?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-03-17 10:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620414131","market":"nz","top_or_hot":-1,"title":"A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue","media":"Simply Wall St.","content":"<div>\n<p>Teva Pharmaceutical Industries (TEVA) is back in focus after investors reacted to progress on its shift from a traditional generics business toward higher margin branded medicines, anchored by Austedo...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 10:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical Industries (TEVA) is back in focus after investors reacted to progress on its shift from a traditional generics business toward higher margin branded medicines, anchored by Austedo...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation-1","article_id":"2620414131","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-pharmaceutical-industries-nyseteva-valuation-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620414131","pubTimestamp":1773714153,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Teva Pharmaceutical Industries (TEVA) is back in focus after investors reacted to progress on its shift from a traditional generics business toward higher margin branded medicines, anchored by Austedo, Ajovy, and Uzedy.\nSee our latest analysis for Teva Pharmaceutical Industries.\nAt a share price of US$29.46, Teva’s recent 3.1% one-day share price return contrasts with a 13.3% decline over 30 days. A very large five-year total shareholder return points to long term momentum supported by its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药","NYSE":"纽交所"},"translate_title":"品牌药品季度收入超过10亿美元后看看梯瓦制药工业公司(NYSE：TEVA)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5,"NYSE":1.5},"content_text":"Teva Pharmaceutical Industries (TEVA) is back in focus after investors reacted to progress on its shift from a traditional generics business toward higher margin branded medicines, anchored by Austedo, Ajovy, and Uzedy. See our latest analysis for Teva Pharmaceutical Industries. At a share price of US$29.46, Teva’s recent 3.1% one-day share price return contrasts with a 13.3% decline over 30 days. A very large five-year total shareholder return points to long term momentum supported by its branded medicines story. If Teva’s shift toward higher margin treatments has caught your attention, it may be a good moment to look at other healthcare names riding similar trends through our screener for 33 healthcare AI stocks With Teva trading at US$29.46, a very large five year total return, ongoing revenue and net income growth, and a wide gap to some valuation estimates, the question is simple: is there still upside here or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 23% Undervalued With Teva at US$29.46 against a narrative fair value of about US$38.05, the current price sits below what that widely followed model suggests.  The analysts have a consensus price target of $23.556 for Teva Pharmaceutical Industries based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $18.0.  Read the complete narrative. Want to understand why this narrative supports a higher fair value than that consensus target range? The core is a long runway for earnings, steady revenue assumptions, firmer margins and a richer future earnings multiple tied to that cash flow profile. Result: Fair Value of $38.05 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on Teva executing its R&D pipeline while managing a heavy net debt load of more than US$15 billion and concentrated exposure to a few key branded drugs. Find out about the key risks to this Teva Pharmaceutical Industries narrative. Another Way to Look at Teva’s Valuation The narrative model points to a fair value of about US$38.05 and calls Teva undervalued, yet the simple earnings multiple tells a different story. At a P/E of 24.3x, Teva trades above the US Pharmaceuticals industry on 17.4x and its own fair ratio of 23.5x. This suggests less margin for error if growth or margins fall short. Which lens feels more realistic to you right now? See what the numbers say about this price — find out in our valuation breakdown. NYSE:TEVA P/E Ratio as at Mar 2026Next Steps With the story so mixed, are you leaning more toward the risks or the rewards here? Take a moment to review the full picture for yourself by weighing up the 4 key rewards and 2 important warning signs Looking for more investment ideas? If Teva has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to hunt for other opportunities that fit your style.  Target stability by reviewing companies that feature a solid balance sheet and fundamentals stocks screener (42 results) and may better match your tolerance for financial risk. Hunt for potential value by sorting through our 47 high quality undervalued stocks, where pricing and fundamentals meet clear, data driven rules. Prioritize consistency of returns by focusing on income ideas from our 15 dividend fortresses and see which payouts currently stand out.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620414131","isCrawlerRequest":true}